Recent News

• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions, and Disorders)
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions, and Disorders)
• 03.20.2025 - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.20.2025 - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.12.2025 - Nektar Therapeutics Q4 2024 Financial Results
• 03.12.2025 - Nektar Therapeutics Q4 2024 Financial Results
• 03.12.2025 - Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.12.2025 - Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.05.2025 - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
• 03.05.2025 - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Recent Filings

• 03.14.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.14.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - 8-K Current report